Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1842-1847

  Van Cutsem, Eric ^a   Rivera, F ^b   Berry, S ^c   Kretzschmar, A ^d   Michael, M ^e   Dibartolomeo, M ^f   Mazier, M A ^g   Canon, J L ^h   Georgoulias, V ⁱ   Peeters, M ^j   Bridgewater, J ^k   Cunningham, D ^l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF TORONTO   (Canada)

^d Section of Pathology   (Germany)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g PAREXEL INTERNATIONAL   (United States)

^h Ctr Hosp Notre Dame Reine Fabiola   (Belgium)

ⁱ UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^l ROYAL MARSDEN HOSPITAL   (United Kingdom)

more..

Author keywords

Bevacizumab; Chemotherapy; Expanded access study; First line; mCRC; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER MORTALITY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; HEART ARREST; HEART INFARCTION; HUMAN; HYPERTENSION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RESPIRATORY TRACT DISEASE; TUMOR REGRESSION; VEIN EMBOLISM; WOUND HEALING IMPAIRMENT;

EID: 66149120036     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp233     Document Type: Article

References (17)

1. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280: C1358-C1366.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
3. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
4. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712.
5. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
6. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
8. Saltz L, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
9. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events. Semin Oncol 2006; 33(5 Suppl. 10): S26-S34.
10. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529.
11. Hedrick E, Kozloff M, Hainsworth J et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BriTE). J Clin Oncol 2006; 24: 18s (Abstr 3536).
12. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
13. Purdie D, Berlin J, Flynn PJ et al. The safety of long-term bevacizumab use: Results from the BriTE observational cohort study. J Clin Oncol 2008; 26: 15s (Abstr 4103).
14. Sugrue MM, Purdie DM, Flynn PJ et al. Serious wound healing complications (WHCs) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: results from the BRiTE Observational Cohort Study Presented at: 2008 Gastrointestinal Cancers Symposium; 25-27 January 2008; Orlando, FL. (Abstr 450). http://www.asco.org (30 January 2008, date last accessed).
15. Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180.
16. Kozloff M, Sugrue MM, Berlin J et al. Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with mCRC: Results from the BRiTE observational cohort study Presented at: 2008 Gastrointestinal Cancers Symposium; 25-27 January 2008; Orlando, FL. (Abstr 450). http://www.asco.org. (30 January 2008, date last accessed).
17. Ellis LM, Haller DG. Bevacizumab beyond progression: Does this make sense? J Clin Oncol 2008; 26: 5313-5315.